Avanafil, a new phosphodiesterase 5 inhibitor to treat erectile dysfunction, has demonstrated a higher selectivity against the inhibition of phosphodiesterase 11.
John Schieszer reports in today’s Medical Minute that because of its chemical makeup this new oral ED medication comes with modest alcohol consumption requirements.
Next post in The Medical Minute
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.